Universität zu Köln

Chen, Robert, Gopal, Ajay K., Smith, Scott E., Ansell, Stephen M., Rosenblatt, Joseph D., Savage, Kerry J., Connors, Joseph M., Engert, Andreas, Larsen, Emily K., Huebner, Dirk, Fong, Abraham and Younes, Anas (2016). Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma. Blood, 128 (12). S. 1562 - 1567. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Full text not available from this repository.

Abstract

Presented here are the 5-year end-of-study results from the pivotal phase 2 trial of brentuximab vedotin in patients with relapsed/refractory (R/R) Hodgkin lymphoma (HL) after failed hematopoietic autologous stem cell transplantation. At 5 years, the overall patient population (N = 102) had an estimated overall survival (OS) rate of 41% (95% confidence interval [CI]: 31-51) and progression-free survival (PFS) rate of 22% (95% CI: 13-31). Patients who achieved a complete response (CR) to brentuximab vedotin (N = 34) had estimated OS and PFS rates of 64% (95% CI: 48-80%) and 52% (95% CI: 34-69%), respectively. The median OS and PFS were not reached in CR patients, with 13 patients (38% of all CR patients) remaining in follow-up and in remission at study closure. Of the 13 patients, 4 received consolidative hematopoietic allogeneic stem cell transplant, and 9 (9% of all enrolled patients) remain in sustained CR without receiving any further anticancer therapy after treatment with brentuximab vedotin. Of the patients who experienced treatment-emergent peripheral neuropathy, 88% experienced either resolution (73%) or improvement (14%) in symptoms. These 5-year follow-up data demonstrate that a subset of patients with R/R HL who obtained CR with single-agent brentuximab vedotin achieved long-term disease control and may potentially be cured. The trial was registered at www.clinicaltrials.gov as #NCT00848926.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Chen, Robert UNSPECIFIED UNSPECIFIED UNSPECIFIED Gopal, Ajay K. UNSPECIFIED UNSPECIFIED UNSPECIFIED Smith, Scott E. UNSPECIFIED UNSPECIFIED UNSPECIFIED Ansell, Stephen M. UNSPECIFIED UNSPECIFIED UNSPECIFIED Rosenblatt, Joseph D. UNSPECIFIED UNSPECIFIED UNSPECIFIED Savage, Kerry J. UNSPECIFIED UNSPECIFIED UNSPECIFIED Connors, Joseph M. UNSPECIFIED UNSPECIFIED UNSPECIFIED Engert, Andreas UNSPECIFIED UNSPECIFIED UNSPECIFIED Larsen, Emily K. UNSPECIFIED UNSPECIFIED UNSPECIFIED Huebner, Dirk UNSPECIFIED UNSPECIFIED UNSPECIFIED Fong, Abraham UNSPECIFIED UNSPECIFIED UNSPECIFIED Younes, Anas UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-262115
DOI:	10.1182/blood-2016-02-699850
Journal or Publication Title:	Blood
Volume:	128
Number:	12
Page Range:	S. 1562 - 1567
Date:	2016
Publisher:	AMER SOC HEMATOLOGY
Place of Publication:	WASHINGTON
ISSN:	1528-0020
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language STEM-CELL TRANSPLANTATION; PHASE-II; INTENSITY; PROGRAM; IMPACT Multiple languages Hematology Multiple languages
Refereed:	Yes
URI:	http://kups.ub.uni-koeln.de/id/eprint/26211